Evidence map›Paper›PMID 39408882›Full record

ArticleInternational journal of molecular sciences2024

Impact of Mygalin on Inflammatory Response Induced by Toll-like Receptor 2 Agonists and IFN-γ Activation.

Nayara Del Santos, Ricardo Vázquez-Ramírez, Elizabeth Mendes, Pedro Ismael Silva Júnior, Monamaris Marques Borges

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nayara Del SantosBacteriology Laboratory, Butantan Institute, São Paulo 05585-000, Brazil.ORCID 0009-0004-4540-5412
Ricardo Vázquez-RamírezInstitute of Biomedical Research, National Autonomous University of Mexico, Mexico City 04510, Mexico.ORCID 0000-0002-7002-0934
Elizabeth MendesBacteriology Laboratory, Butantan Institute, São Paulo 05585-000, Brazil.
Pedro Ismael Silva JúniorLaboratory for Applied Toxinology (LETA), Butantan Institute, São Paulo 05585-000, Brazil.ORCID 0000-0001-6619-6489
Monamaris Marques BorgesBacteriology Laboratory, Butantan Institute, São Paulo 05585-000, Brazil.ORCID 0000-0001-8355-5498

Funding

CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) 472744/2012-7FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) 2013/07467-1FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) 2020/08182-4FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) 2023/08292-2
6 · The paper itself

Abstract

Several natural products are being studied to identify new bioactive molecules with therapeutic potential for infections, immune modulation, and other pathologies. TLRs are a family of receptors that play a crucial role in the immune system, constituting the first line of immune defense. They recognize specific products derived from microorganisms that activate multiple pathways and transcription factors in target cells, which are vital for producing immune mediators. Mygalin is a synthetic acylpolyamine derived from hemocytes of the spider

Indexed as

Interferon-gammaToll-Like Receptor 2AnimalsHumansInflammationInterleukin-6LipopeptidesMiceMolecular Docking SimulationPolysaccharidesRAW 264.7 CellsSignal TransductionTranscription Factor RelAZymosanInterferon-gammaInterleukin-6LipopeptidesPam(3)CSK(4) peptidePolysaccharidesToll-Like Receptor 2Transcription Factor RelAZymosanacylpolyaminecytokinesinflammationmolecular dockingmygalinTLR

Identifiers

PMID39408882
PMCPMC11476598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.